Semaglutide

Obesity has become a global epidemic, and the incidence of obesity continues to soar in countries around the world. The World Health Organization (WHO) estimates that 13% of adults worldwide suffer from obesity. What's more, obesity can further lead to metabolic syndrome with complications such as type 2 diabetes, high blood pressure, nonalcoholic steatohepatitis (NASH), cardiovascular disease, and cancer.

In June 2021, the FDA approved the marketing of Semaglutide, a weight-loss drug developed by Novo Nordisk, under the trade name Wegovy. Due to its excellent weight loss effect, good safety, and driven by celebrities such as Musk, semaglutide has swept the world, and even a drug is hard to find.